Molecular marker related to rectal cancer and application thereof

Abstract

The invention relates to a molecular marker related to the rectal cancer and application thereof, and belongs to the technical field of the medical molecular biology. According to the invention, two key designs are carried out; one design is that ctDNA detection is carried out by applying a whole-exon big panel of 425 cancer-related genes instead of a small panel of a small number of hotspot genes, so that not only is relevance between one single gene mutation and an nCRT treatment effect obtained, but also relevance between genetic mutations of a plurality of signal channels and the nCRT treatment effect is obtained; and the other design is that a plurality of monitoring time points (four time points) are set before an operation, the big panel of the 425 genes is combined, and meanwhile,elimination of the mutations in the ctDNA and dynamic changes of acquired mutations are monitored. Value of ctDNA dynamic monitoring in predication of the nCRT treatment effect is shown, and a new opinion is proposed for a patient adopting a W&W strategy. The invention proves effects of ctDNA detection in the early period of predicting the prognosis of an LARC patient.

Description

technical field [0001] The invention relates to a molecular marker related to rectal cancer and its use, belonging to the technical field of medical molecular biology. Background technique [0002] Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related death worldwide. Rectal cancer accounts for approximately 30% of CRCs, and locally advanced rectal cancer (LARC) accounts for 50% of all rectal cancers. Currently, neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision (TME) combined with adjuvant chemotherapy is the standard treatment for LARC recommended by the National Comprehensive Cancer Network (NCCN) guidelines. About 10-35% of nCRT patients can achieve pathological complete response (pCR) at the time of surgery. Patients with pCR have a better prognosis, less local recurrence and distant metastasis, and a higher 5-year overall survival rate. However, conventional radical surgery may lead to serious complica...

AI Technical Summary

Problems solved by technology

[0003] Circulating tumor DNA (ctDNA) has been used as a predictor of chemotherapy response in metastatic colorectal cancer, however few studies have explored the role of ctDNA in predicting pathological response to nCRT in LARC patients

Furthermore, ctDNA has shown value in early recurrence detection after adjuvant chemotherapy in colon cancer patients, but the potential role of ctDNA in risk stratification and treatment strategy guidance after nCRT in LARC patients has not been fully evaluated

Images